Tasos Konidaris - Mar 1, 2024 Form 4 Insider Report for Amneal Pharmaceuticals, Inc. (AMRX)

Signature
/s/ Denis Butkovic, Attorney-in-Fact
Stock symbol
AMRX
Transactions as of
Mar 1, 2024
Transactions value $
-$269,562
Form type
4
Date filed
3/5/2024, 04:56 PM
Previous filing
Mar 14, 2023
Next filing
Mar 14, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AMRX Class A Common Stock Options Exercise +36.2K +9.5% 417K Mar 1, 2024 Direct F1, F2
transaction AMRX Class A Common Stock Tax liability -$72.5K -13.3K -3.18% $5.47 404K Mar 1, 2024 Direct F3
transaction AMRX Class A Common Stock Options Exercise +45.3K +11.22% 449K Mar 3, 2024 Direct F1, F2
transaction AMRX Class A Common Stock Tax liability -$87K -15.9K -3.54% $5.47 433K Mar 3, 2024 Direct F3
transaction AMRX Class A Common Stock Options Exercise +57.3K +13.24% 491K Mar 3, 2024 Direct F1, F2
transaction AMRX Class A Common Stock Tax liability -$110K -20.1K -4.1% $5.47 470K Mar 3, 2024 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AMRX Restricted Stock Units Options Exercise $0 -36.2K -50% $0.00 36.2K Mar 1, 2024 Class A Common Stock 36.2K Direct F2, F4
transaction AMRX Restricted Stock Units Options Exercise $0 -45.3K -33.33% $0.00 90.6K Mar 3, 2024 Class A Common Stock 45.3K Direct F2, F5
transaction AMRX Restricted Stock Units Options Exercise $0 -57.3K -25% $0.00 172K Mar 3, 2024 Class A Common Stock 57.3K Direct F2, F6
transaction AMRX Restricted Stock Units Award $0 +176K $0.00 176K Mar 4, 2024 Class A Common Stock 176K Direct F2, F7
transaction AMRX Performance-Based Restricted Stock Units Award $0 +352K $0.00 352K Mar 4, 2024 Class A Common Stock 352K Direct F8, F9
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3.
F2 Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.
F3 Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units.
F4 On March 1, 2021, the reporting person was granted 144,788 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date.
F5 On March 3, 2022, the reporting person was granted 181,159 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date.
F6 On March 3, 2023, the reporting person was granted 229,358 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date.
F7 The restricted stock units vest in four equal annual installments beginning on March 4, 2025.
F8 Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.
F9 Represents a performance-based restricted stock unit grant of 175,926 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing price per share targets at the end of the three-year performance period. The number of shares that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2027, the last day of the performance period.